| Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer |
Androgen deprivation therapy, Flibanserin 100 MG, Placebo |
Recruiting |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients |
Biospecimen Collection, Letermovir |
Not yet recruiting |
| Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial |
Laser Therapy, Quality of Life Assessment, Questionnaire Administration, Sham Intervention |
Not yet recruiting |
| Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors |
Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration |
Not yet recruiting |
| Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy |
|
Enrolling by invitation |
| Learning Collaborative Vs Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer |
Technical Assistance, Virtual Learning Collaborative |
Enrolling by invitation |
| Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy |
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Wound Dressing Material |
Active, not recruiting |
| Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors |
Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration |
Active, not recruiting |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis |
Infliximab, Intravenous Immunoglobulin Therapy, Prednisone, Quality-of-Life Assessment, Questionnaire Administration |
Active, not recruiting |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer |
Endocrine therapy interruption |
Active, not recruiting |